Topical application of imiquimod induces alternations in peripheral blood lymphocytes in healthy individuals

Acta Dermato-Venereologica

Volumn 89, Issue 2, 2009, Pages 134-139

  Pasmatzi, Efi ^a   Chaidaroglou, Antigoni ^a   Sakkis, Theophilos ^a   Monastirli, Alexandra ^a   Georgiou, Sophia ^a   Sagriotis, Alexandros ^a   Badavanis, George ^a   Vryzaki, Eleftheria ^a   Matsouka, Panagiota ^b   Degiannis, Dimitrios ^a   Tsambaos, Dionysios ^a  

^a UNIVERSITY OF PATRAS   (Greece)

^b Onassis Cardiac Surgery Center   (Greece)

Author keywords

Flow cytometry; Imiquimod; Immunomodulation; Immunophenotyping; Lymphocyte subsets

Indexed keywords

IMIQUIMOD;

ADULT; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG TOLERABILITY; FLOW CYTOMETRY; HUMAN; HUMAN EXPERIMENT; IMMUNOMODULATION; INNATE IMMUNITY; LYMPHOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; MEMORY T LYMPHOCYTE; NORMAL HUMAN; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; SIDE EFFECT; T LYMPHOCYTE; TREATMENT DURATION; TREATMENT RESPONSE;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, CUTANEOUS; ADULT; AMINOQUINOLINES; ANTIGENS, CD; HLA-DR ANTIGENS; HUMANS; LYMPHOCYTE SUBSETS; LYMPHOCYTES; MALE; MIDDLE AGED; TOLL-LIKE RECEPTOR 7; TOLL-LIKE RECEPTOR 8;

EID: 63049087301     PISSN: 00015555     EISSN: None     Source Type: Journal    
DOI: 10.2340/00015555-0597     Document Type: Article

References (36)

1. Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, et al. Small anti-viral compounds activate immune cells via the TLR7 My88-signaling pathway. Nat Immunol 2002; 3: 196-200.
2. Bilu D, Sauder DN. Imiquimod: modes of action. Br J Dermatol 2003; 149: 5-8.
3. Hengge UR, Ruzicka Th. Topical immunomodulation in dermatology: potential of Toll-like receptor agonists. Dermatol Surg 2004; 30: 1101-1112.
4. Badavanis G, Monastirli A, Pasmatzi E, Tsambaos D. Successful treatment of granuloma annulare with imiquimod cream 5%: a report of four cases. Acta Derm Venereol 2005; 85: 547-548.
5. Tsambaos D, Chaidaroglou A, Sakkis Th, Sagriotis A, Georgiou S, Badavanis G, et al. Topical Toll-like receptor agonists: a new era in cutaneous immunotherapy. Rev Clin Pharmacol Pharmacokin 2006; 20: 341-343.
6. Georgiou S, Monastirli A, Pasmatzi E, Tsambaos D. Pyogenic granuloma: complete remission under occlusive imiquimod 5% cream. Clin Exp Dermatol 2008; 33: 454-456.
7. Schön MP, Schön M. Imiquimod: mode of action. Br J Dermatol 2007; 157: 8-13.
8. Suzuki H, Wang B, Shivji G, Toto P, Amerio P, Tomai MA, et al. Imiquimod, a topical immune response modifier, induces migration of Langerhans cells. J Invest Dermatol 2000; 114: 135-141.
9. Stanley MA. Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential. Clin Exp Dermatol 2002; 27: 571-577.
10. Schiller M, Metze D, Luger ThA, Grabbe S, Gunzer M. Immune response modifiers - mode of action. Exp Dermatol 2006; 15: 331-341.
11. Loken MR, Brosnan JM, Bach BA, Ault KA. Establishing optimal lymphocyte gates for immunophenotyping by flow cytometry. Cytometry 1990; 11: 453-459.
12. Webster GA, Bowles MJ, Karim MS, Wood RF, Pockley AG. Flow cytometric analysis of peripheral blood lymphocyte subset light scatter characteristics as a means of monitoring the development of rat small bowel allograft rejection. Clin Exp Immunol 1995; 100: 536-542.
13. Witt PL, Ritch PS, Reding D, McAuliffe TL, Westrick L, Grossberg SE, Borden EC. Phase I trial of an oral immunomodulator and interferon inducer in cancer patients. Cancer Res 1993; 53: 5176-5180.
14. Savage P, Horton V, Moore J, Owens M, Witt P, Gore ME. A phase I clinical trial of imiquimod, an oral interferon inducer, administered daily. Br J Cancer 1996; 74: 1482-1486.
15. Goldstein D, Hertzog P, Tomkinson E, Couldwell D, McCarville S, Parrish S, et al. Administration of imiquimod, an interferon inducer, in asymptomatic human immunodeficiency virus-infected persons to determine safety and biologic response modification. J Infect Dis 1998; 178: 858-861.
16. Harrison CJ, Jenski L, Voychehovski T, Bernstein DI. Modification of immunological responses and clinical disease during topical R-837 treatment of genital HSV-2 infection. Antivir Res 1988; 10: 209-223.
17. Harrison CJ, Miller RL, Bernstein DI. Posttherapy suppression of genital herpes simplex virus recurrences and enhancement of HSV-specific T-cell memory by imiquimod in guinea pigs. Antimicrob Agents Chemother 1994; 38: 2059-2064.
18. Redondo P, del Olmo J, Lopez-Diaz de Cerio A, Inoges S, Marquina M, Melero I, et al. Imiquimod enhances the systemic immunity attained by local cryosurgery destruction of melanoma lesions. J Invest Dermatol 2007; 127: 1673-1680.
19. Benson E. Imiquimod: potential risk of an immunostimulant. Austral J Dermatol 2004; 45: 123-124.
20. Rajan N, Langtry JA. Generalized exacerbation of psoriasis associated with imiquimod cream treatment of superficial basal cell carcinomas. Clin Exp Dermatol 2006; 31: 140-141.
21. Fanti PA, Dika E, Vaccari S, Miscial C, Varotti C. Generalized psoriasis induced by topical treatment of actinic keratosis with imiquimod. Int J Dermatol 2006; 45: 1464-1465.
22. Gilliet M, Conrad C, Geiges M, Cozzio A, Thürlimann W, Burg G, et al. Psoriasis triggered by Toll-like receptor 7 agonist imiquimod in the presence of dermal plaqsmacytoid dendritic cell precursors. Arch Dermatol 2004; 140: 1490-1495.
23. Wolfe CM, Tafuri N, Harfield K. Exacerbation of myasthenia gravis during imiquimod treatment. J Drugs Dermatol 2007; 6: 745-746.
24. Barba AR, Kapoor S, Berman B. An open label safety study of topical imiquimod 5% cream in the treatment of molluscum contagiosum in children. Dermatology Online 2001; 7: 20-25.
25. Marks R, Gebauer K, Shumack S, Amies M, Bryden J, Fox TL, Owens ML; Australasian Multicentre Trial Group. Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose-response trial. J Am Acad Dermatol 2001; 44: 807-813.
26. Agarwall S, Berth-Jones J. Porokeratosis of Mibelli: successful treatment with 5% imiquimod cream. Br J Dermatol 2002; 146: 331-344.
27. Muzio G, Massone C, Rebora A. Treatment of non-genital warts with topical imiquimod 5% cream. Eur J Dermatol 2002; 12: 347-349.
28. Florez A, Feal C, de la Torre C, Cruces M. Invasive squamous cell carcinoma treated with imiquimod 5% cream. Acta Derm Venereol 2004; 84: 227-228.
29. Harrison LI, Skinner SL, Marbury TC, Owens ML, Kurup S, MaKane S, Greene RJ. Pharmacokinetics and safety of imiquimod 5% cream in the treatment of actinic keratoses of the face, scalp, or hands and arms. Arch Dermatol Res 2004; 296: 6-11.
30. Schulze HJ, Cribier B, Requena L, Reifenberger J, Ferrandiz C, Garcia Diez A, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe. Br J Dermatol 2005; 152: 939-947.
31. Myhre PE, Levy ML, Eichenfield LF, Kolb VB, Fielder SL, Meng T-C. Pharmacokinetics and safety of imiquimod 5% cream in the treatment of molluscum contagiosum in children. Ped Dermatol 2008; 25: 88-95.
32. Schartz NES, Chevret S, Paz C, Kerob D, Verola O, Morel P, Lebbe C. Imiquimod 5% cream for treatment of HIV-negative Kaposi's sarcoma skin lesions: a phase I to II, open-label trial in 17 patients. Am Acad Dermatol 2008; 58: 585-591.
33. Li VW. Imiquimod as an antiangiogenic agent. J Drug Dcrmatol 2005; 4: 708-717.
34. Ulrich C, Bichel J, Euvrard S, Guildi B, Proby CM, van de Kerkhof PCM, et al. Topical immunomodulation under systemic immunosuppression: results of a multicentre, randomized, placebo-controlled safety and efficacy study of imiquimod 5% cream for the treatment of actinic keratoses in kidney, heart, and liver transplant patients. Br J Dermatol 2007; 157: 25-31.
35. Pruvost C, Penso-Assathiany D, Bachor N, Lang P, Roujeau JC. Risk factors for cutaneous wart onset in transplant recipients. Ann Dermatol Venereol 2002; 129: 291-293.
36. Schmook T, Nindl I, Ulrich C, Meyer T, Sterry W, Stockfleth E. Viral warts in organ transplant recipients: new aspects in therapy. Br J Dermatol 2003; 149: 20-24.